Roosevelt Investment Group Inc. decreased its stake in Johnson & Johnson (NYSE:JNJ) by 20.2% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 164,513 shares of the company’s stock after selling 41,635 shares during the period. Johnson & Johnson makes up 1.9% of Roosevelt Investment Group Inc.’s portfolio, making the stock its 17th largest position. Roosevelt Investment Group Inc.’s holdings in Johnson & Johnson were worth $19,962,000 at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in the business. R.M.SINCERBEAUX Capital Management LLC grew its stake in Johnson & Johnson by 11.7% in the 2nd quarter. R.M.SINCERBEAUX Capital Management LLC now owns 3,652 shares of the company’s stock worth $443,000 after buying an additional 382 shares in the last quarter. Tufton Capital Management lifted its holdings in shares of Johnson & Johnson by 0.4% in the 2nd quarter. Tufton Capital Management now owns 88,258 shares of the company’s stock worth $10,709,000 after acquiring an additional 382 shares during the last quarter. SFE Investment Counsel lifted its holdings in shares of Johnson & Johnson by 1.8% in the 2nd quarter. SFE Investment Counsel now owns 22,110 shares of the company’s stock worth $2,683,000 after acquiring an additional 383 shares during the last quarter. Capital Advantage Inc. lifted its holdings in shares of Johnson & Johnson by 4.4% in the 2nd quarter. Capital Advantage Inc. now owns 9,436 shares of the company’s stock worth $1,145,000 after acquiring an additional 394 shares during the last quarter. Finally, Sather Financial Group Inc lifted its holdings in shares of Johnson & Johnson by 3.7% in the 2nd quarter. Sather Financial Group Inc now owns 11,051 shares of the company’s stock worth $1,341,000 after acquiring an additional 399 shares during the last quarter. 66.51% of the stock is currently owned by institutional investors and hedge funds.
NYSE:JNJ opened at $145.91 on Friday. Johnson & Johnson has a 1-year low of $118.62 and a 1-year high of $148.99. The stock has a market capitalization of $391.78 billion, a PE ratio of 19.99, a price-to-earnings-growth ratio of 2.28 and a beta of 0.59. The company has a current ratio of 1.72, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 16th. The company reported $2.05 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.03 by $0.02. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The company had revenue of $20.35 billion for the quarter, compared to the consensus estimate of $20.05 billion. During the same period in the prior year, the firm posted $1.90 EPS. Johnson & Johnson’s revenue for the quarter was up 3.6% on a year-over-year basis. On average, analysts forecast that Johnson & Johnson will post 8.16 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 11th. Investors of record on Tuesday, November 27th will be given a dividend of $0.90 per share. This represents a $3.60 annualized dividend and a yield of 2.47%. The ex-dividend date of this dividend is Monday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 49.32%.
A number of research firms recently commented on JNJ. Raymond James upped their price target on shares of Johnson & Johnson from $144.00 to $149.00 and gave the company an “outperform” rating in a report on Wednesday, October 17th. Credit Suisse Group upped their price target on shares of Johnson & Johnson from $149.00 to $152.00 and gave the company an “outperform” rating in a report on Wednesday, October 17th. Citigroup upped their price target on shares of Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a report on Monday, October 22nd. Zacks Investment Research lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Tuesday. Finally, Wells Fargo & Co reiterated an “outperform” rating and set a $160.00 price target (up from $155.00) on shares of Johnson & Johnson in a report on Wednesday, October 17th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $143.90.
In related news, EVP Michael E. Sneed sold 30,943 shares of the stock in a transaction dated Friday, November 23rd. The shares were sold at an average price of $142.46, for a total transaction of $4,408,139.78. Following the sale, the executive vice president now directly owns 70,817 shares of the company’s stock, valued at approximately $10,088,589.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Ronald A. Kapusta sold 8,441 shares of the firm’s stock in a transaction dated Thursday, November 8th. The shares were sold at an average price of $145.15, for a total transaction of $1,225,211.15. Following the sale, the chief accounting officer now directly owns 17,284 shares in the company, valued at approximately $2,508,772.60. The disclosure for this sale can be found here. Insiders have sold a total of 510,544 shares of company stock worth $74,414,877 over the last three months. 0.22% of the stock is currently owned by insiders.
TRADEMARK VIOLATION WARNING: “Roosevelt Investment Group Inc. Lowers Holdings in Johnson & Johnson (JNJ)” was originally published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://transcriptdaily.com/2018/12/07/roosevelt-investment-group-inc-lowers-holdings-in-johnson-johnson-jnj.html.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
Further Reading: How accurate is the Rule of 72?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.